Trial Profile
Targeting Polyamines Using DFMO in Persons With Type 1 Diabetes: A Randomized, Double-Masked, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Initial Pharmacodynamics of Multiple Ascending Doses
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs Eflornithine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 02 Nov 2023 According to a Panbela Media Release, data published in the journal Cell Reports Medicine.
- 02 Nov 2023 According to a Panbela Media Release, the trial supported by the funding from JDRF
- 26 Jun 2023 According to a Panbela Media Release, results from this study were presented at the Endocrine Society meeting, which was held June 15-18, 2023.